Medusa Pharmaceuticals Analysis: $13.8 Raised
What is Medusa Pharmaceuticals?
Medusa Pharmaceuticals is an Imperial College London spin-out focused on overcoming antimicrobial resistance through novel synergistic drug combinations. The company develops repurposed drug pairings that restore efficacy of existing antibiotics against resistant bacteria. This approach targets the evolutionary adaptation of bacteria to survive antibiotic treatment.
Location
Cambridge, United Kingdom
Employees
1-10
Founded
2021
Funding Status
Seed
Product Features & Capabilities
- Synergistic drug combinations to restore antibiotic efficacy
- Repurposed drug pairings for AMR treatment
Use Cases
Restore penicillin effectiveness against resistant strains; Enhance treatment of tuberculosis with existing drugs; Improve outcomes for cystic fibrosis patients with Pseudomonas aeruginosa
Other Considerations
Imperial College London spin-out; Focus on AMR with global health impact; Addresses a growing threat of 1 million annual deaths from AMR
See something that needs updating? Suggest edits to this profile.